Skip to main content
OpenTrials

Clinical trial condition

Poxviridae Infections

Explore clinical trials studying Poxviridae Infections. Study availability and eligibility vary by location and protocol.

164 public trials 17 recruiting studies
Refine in advanced search Browse all conditions

Poxviridae Infections trial results

Completed

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

NCT03927716

Conditions
DNA Virus Infections, Infections, Molluscum Contagiosum, +6 more
Locations
  • Site #218 Mobile, Alabama, United States
  • Site #312 Glendale, Arizona, United States
  • Site #298 Little Rock, Arkansas, United States
  • Site #272 Rogers, Arkansas, United States
View all 35 locations
View Trial Details
Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose

NCT00001056

Conditions
Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +14 more
Locations
  • St. Louis Univ. School of Medicine AVEG St Louis, Missouri, United States
  • Univ. of Rochester AVEG Rochester, New York, United States
  • Vanderbilt Univ. Hosp. AVEG Nashville, Tennessee, United States
View Trial Details
Completed

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules

NCT00000957

Conditions
Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +14 more
Locations
  • St. Louis Univ. School of Medicine AVEG St Louis, Missouri, United States
  • JHU AVEG Pittsburgh, Pennsylvania, United States
  • Vanderbilt Univ. Hosp. AVEG Nashville, Tennessee, United States
View Trial Details
Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals

NCT00001026

Conditions
Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +14 more
Locations
  • Univ. of Rochester AVEG Rochester, New York, United States
  • UW - Seattle AVEG Seattle, Washington, United States
View Trial Details
Completed

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

NCT00001043

Conditions
Blood-Borne Infections, Communicable Diseases, DNA Virus Infections, +15 more
Locations
  • St. Louis Univ. School of Medicine AVEG St Louis, Missouri, United States
  • UW - Seattle AVEG Seattle, Washington, United States
View Trial Details

Related conditions